Phylloceuticals’ scientists are world leading experts in genetically modified plants to produce proteins for therapeutics. The company offers two complementary bio-production which offer advantages across a spectrum of human therapeutic proteins:
These growth formats offer advantages for different production needs:
1. Vertical – Transient genetically modified tobacco bioproduction format – can produce kgs / week within 3 weeks notice
2. Aquaculture - Lemna bioproduction format
PHYLLOCEUTICALS brings these platforms together in one offering
Biologics and vaccines can now be rapidly manufactured and delivered locally by regionally employing the PMP platform. Plants grow quickly and can be transfected to produce required human therapeutics without the capital expense of traditional stainless steel bioreactor infrastructure.
Over the last 30 years, advancements in recombinant technologies have been used to produce therapeutic biologic molecules, i.e. antibodies, vaccines, peptides, and others. The PMP sector has grown too, and many biologics and vaccines have emerged in the PMP space.
The 2020 pandemic focused the world on food security and pharmaceutical security. Every country is evaluating ways to manufacture and supply their citizens with needed medicines. Phylloceuticals is keenly aware of this dynamic and is focused on providing underserved markets in the US and globally. The PhAAST™ technology provides a rapid manufacturing platform to address cancer, infectious disease, and chronic disease.
Our response to these opportunities is to provide Phytopharma As A Sustainable Technology (PhAAST™) to global customers in both developed and developing regions.